Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

254.19 +12.73 (+5.27%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna: 3 Key Takeaways for Long-Term Investors ↗
Its proprietary software is built into the cancer drug itself, creating a front-end design moat that rivals may struggle to replicate. 
Via The Motley Fool
Topics Earnings
S&P 500 Top Movers: Nov. 6, 2026 Gainers and Losers ↗
Via Chartmill
Topics Stocks
News headline image
Why is Moderna (MRNA) stock soaring today
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 finan... 
Via StockStory
News headline image
Moderna (MRNA) Q3 2026 Earnings Call Transcript ↗
Profitability returned as international partnerships offset a norovirus setback. 
Via The Motley Fool
Topics Earnings
Moderna (NASDAQ:MRNA) Q3 Earnings Beat and Raised Guidance Fuel Stock Rally ↗
Via Chartmill
Topics Earnings
News headline image
What Moderna (MRNA) Said on Its Q3 Earnings Call ↗
Moderna (NASDAQ:MRNA) raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Moderna Just Gave Investors Yet Another Thing to Cheer About ↗
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too. 
Via The Motley Fool
News headline image
Moderna (NASDAQ:MRNA) delivers strong Q3 2026 numbers, stock soars
Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 29.2% year on year to $1.31 b... 
Via StockStory
News headline image
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38 Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up... 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA ® , and combination influenza and COVID-19 vaccine, mCOFLU ® 
From Moderna, Inc.
Via ACCESS Newswire
S&P 500 After-Hours Movers: ABNB and SNDK Gain, AXON and SOLV Fall ↗
Via Chartmill
Topics Stocks
News headline image
Moderna (MRNA) Q3 earnings report preview: what to look for
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting earnings this Friday before market hours. Here’s what to expect. Moderna beat analysts’ revenue... 
Via StockStory
Topics Artificial Intelligence
News headline image
Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical stocks trade up, what you need to know
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat... 
Via StockStory
News headline image
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success ↗
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge. 
Via The Motley Fool
News headline image
Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside. 
Via MarketBeat
Topics Artificial Intelligence Earnings Initial Public Offering
News headline image
Could Investing in Moderna's Stock Double Your Money? ↗
The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future. 
Via The Motley Fool
News headline image
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started ↗
Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma. 
Via The Motley Fool
News headline image
Stock Split Watch: Is Moderna Next? ↗
Moderna stock has skyrocketed this year. 
Via The Motley Fool
News headline image
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away ↗
These biotechs’ valuations are through the roof. 
Via The Motley Fool
News headline image
Will Moderna Soar on Nov. 6? ↗
Moderna shares have outperformed tech giants this year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility ↗
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size. 
Via The Motley Fool
News headline image
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved. 
Via MarketBeat
S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fall ↗
Via Chartmill
Topics Stocks
S&P 500 Gap-Down Stocks for Oct. 26, 2026 ↗
Via Chartmill
Topics Stocks
S&P 500 Premarket Movers: Gainers and Losers Before the Open ↗
Via Chartmill
Topics Stocks
News headline image
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
From Biotech Insider
Via GlobeNewswire
News headline image
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial ↗
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The... 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback